TWI329518B - Medicine-release biochip - Google Patents

Description

1329518 On June 2, 099, the shuttle is justified. 6. Description of the Invention: [Technical Field of the Invention] [0001] The present invention relates to a biofilm for drug release, in particular to an implanted human body and reproducibly timed quantitative The release of the drug into the human biochip. [Previous Technology] [0002] With the advent of the new era, the medical and pharmaceutical industry, both at home and abroad, is facing many technical bottlenecks that traditional medical methods cannot surpass. In addition to the innovation and enhancement of knowledge research, it is indisputable that in many medical practical operation technologies, it is also necessary to rely on novel technologies in various fields of the new era to solve and improve the problem of X-ray technology and artificial organs. , laser surgery, bio-wafers, etc., in the display of medical research and scientific research has become an inseparable integral two sides of beta

[0003] Medically, sometimes for certain special cases or for the treatment of certain patients, it is necessary to apply a drug treatment to the patient for a long-term and periodic manner, such as injection or oral medication or even surgery. Surgery, etc., and the cycle is also different according to different cases, perhaps one month, one week, two days, two days, one day, the patient report may have to face frequent and inevitable treatment process of the sickle and needle. It will take a lot of time for patients to go to hospitals and other registrations, and the other will increase the pain and pressure of patients during the treatment process. Therefore, the automatic drug release system in the body has been long-lasting. One of the important technologies that have been very much anticipated in medicine. [0004] 095145276 Currently in the medical world, the human body-based drug release line technology is still in the form number Α0101 Page 3 / 14 pages 0993195987-0 1329518 099 June 2, according to the positive replacement page step stage, because this On one hand, it involves the exclusion of foreign substances from the human body. On the other hand, it involves the adaptation of the human body to implanted objects. If the size of the implant is too large, it will not only cause discomfort to the human body, but also increase the implantation. The body is affected by the impact of the human body. In addition, how to release a certain dose to the human body at regular intervals, as well as the replacement cycle of the implant must be solved at the same time. Also, due to the numerous factors to be considered, there is still no widespread product.

[0005] The more mature technology in practical human implant application is the contraceptive device Norplant, which is a mechanism for human body to release lutein, which is composed of six match-shaped long-acting release contraceptive sacs. The physician implants under the skin (usually on the inside of the upper arm) slowly releases the birth control pill in the human body to inhibit ovulation, atrophy of the endometrium, and interference with the fallopian tubes and cervical mucus. The entire implantation process takes about 10-15 minutes, and the removal takes about 20-40 minutes. The wound is only about 0.3 cm, and the position is inside the arm, so it is not easy to be found. In addition, the local anesthetic is injected during the implantation process, so it does not feel pain. If you want to get pregnant, you can take it out at any time. The contraceptive effect lasts for five years, and the contraceptive effect is almost 100%. This is a successful drug release in the body. System case. [0006] In addition to the general human body implanted with Nopland that releases lutein, researchers at the Swiss Federal Institute of Science and Technology recently invented a treatment using subcutaneous implantable capsules instead of injections. According to the materials provided by the Swiss National Research Centre, the main process of this treatment is that the researchers perform local anesthesia for the patient and implant a coin-sized capsule on the forearm, which takes less than 5 minutes. The capsule contains active substances such as erythropoietin, and in the following months or even years, these activities 095,145,276 Form No. A0101 Page 4 / Total 14 Page 0993195987-0 Correction of Substrate Substance on June 2, 099 It will continue to penetrate into the patient's body and has an effective therapeutic effect on patients with anemia, hemophilia and diabetes. We know that a patient with severe anemia usually needs to perform three times of erythropoietin input per week to maintain normal functioning of the human body. If subcutaneous implantation is used, the trouble of frequent injections can be eliminated. However, this application mechanism is still in the experimental stage, and many problems encountered, such as the time control of the release of the drug, and the dose control of the drug permeation in the capsule, etc., have yet to be further solved. After the clinical trial results are completed, it will be expected to become the gospel of the medical community. There is also an important example of JT Santini Jr, MJ Cima, and R. [anger, the Massachusetts Institute of Technology (MIT), who published a revolutionary drug on January 28, 1999 in Nature. The transfer method, that is, the use of microchips (micr〇chips) to deliver drugs. This is a long-acting drug microchip. They designed a Shixi microchip that is the size of a dime coin. The off-type Shishi microchip has 34 small storage chambers like small pinholes (and can be further expanded to at least 1,400). Small storage compartments Each small storage compartment can store approximately 25 nL (nL is a billionth of a liter) of solid, liquid or gelled drug, and the small storage compartment is covered with a film made of gold. The drug release in the small storage chamber is to melt the gold thin cover of the small storage chamber by electrochemical reaction, so the gold thin cover is also used as the anode at the same time, and the other electrodes on the micro wafer are used as the cathode and then externally connected to a small battery; Then, according to the set time, the gold thin cover of the small storage room can be melted, and the small storage of the medicine is released. Although this prototype 矽 microchip is externally connected to a small battery, it can also be designed as a completely independent device. This device can be replaced by micro-form number A0101 page 5/14 pages 0993195987-0 099 The page is pre-programmed, implanted under the skin or the peritoneum, and then controlled by wire or wireless. _]This

Solid-length drug-release microchips can benefit many patients immediately. For example, chronic patients who need long-term medical treatment, patients with poor memory, often take medication, and need to treat with very small amounts of high-efficiency analgesics. Patients with sexual pain, etc. It can also be used for the treatment of contraception or infertility. Special supplements for the elderly or women. Since such a wafer needs to be arranged with extremely fine circuits, it is still impossible to balance the cost, manufacturing technology and practicality. Therefore, the drug device is still only in the experimental stage and cannot be a finished product. [〇〇〇9] In short, the in vivo drug release device can be said to be the current trend in the development of the medical industry. It is also the focus of the medical technology industry actively seeking breakthroughs, and with the advancement of biotechnology and the growing popularity of nanotechnology. We can see that these special institutions that were not possible in the past will be realized one by one in the future and used by human beings. [Summary of the Invention]

[0010] It is an object of the present invention to create a biochip that can be implanted into a human body while at the same time taking into account both the timing and the quantitative release of the drug. [0011] In order to achieve the above object, the present invention provides a drug release biochip implanted in a human body for releasing a drug to the human body, the biochip comprising: a drug-loading substrate having a plurality of a groove, the groove respectively carrying the drug; a casing disposed above the drug-loading substrate and covering the drug-loading substrate, the casing further comprising an opening; and a rotary actuating mechanism Between the planting substrate and the outer hub, and driving the outer casing to rotate above the base of the medicinal plant; thereby, when the opening is followed by 095145276, the form number is Α0101, page 6/14 pages, 09丨1329518, 099, June 02. Correction Replacement Page When the outer casing is rotated and sequentially passes over the plurality of grooves, the medicine in the plurality of grooves is released to the human body through the opening. [0012] For the purpose of further achieving the present invention, the drug-loading substrate of the drug-released biochip of the present invention further comprises a film covering the plurality of grooves for preserving the drug that has not been released into the human body. And wherein the sealing film is soluble in the blood of the human body.

[0013] In order to further achieve the object of the present invention, the rotary actuation mechanism of the drug release biofilm of the present invention further comprises a shaft axis, wherein the shaft axis comprises an automatic clock machine core and a clockwork mechanism, and the shaft shaft The heart is machined in a micro-micro mechanical process. The shaft axis further passes through the drug-loading substrate and protrudes from the outer casing to drive the outer casing to rotate above the drug-loading substrate. [Embodiment]

[0014] Some exemplary embodiments embodying the features and advantages of the present invention are described in detail in the following description. It is to be understood that the present invention is capable of various modifications in various aspects, and the description and illustration are in the nature of [0015] The present invention is an invention produced across a plurality of technical fields, using a microelectromechanical (MEMS) process to shrink a drug release mechanism that can simultaneously take care of both timing and quantification into a microscopic biochip. The biochip is used as a drug-loading substrate for medical drugs, and is implanted in a subcutaneous or abdomen of a human body, and can be periodically and quantitatively released to provide long-term and repetitive treatment in the medical field. A more comfortable, convenient and time-saving method for the application of drugs in the human body 095145276 Form No. A0101 Page 7 of 14 0993195987-0 1329518 I 099 June [0016] Please also refer to the first figure and the 2 is a front view of a preferred embodiment, and a second side view is a side cross-sectional view of a preferred embodiment of the present invention. As shown, the biofilm 10 in which the drug is released in this case comprises a drug-loading substrate 11, a casing 丨2, and a rotary actuator 13. In the embodiment, the drug-loading substrate is a micro-volume circular wafer, and a plurality of grooves 111 are opened in a circular shape on the front surface of the drug-loading substrate 11 for carrying the drug 14. Of course, at the time of manufacture, the groove 111 can appropriately change factors such as the number, depth, width, and shape of the groove depending on the type and amount of the drug 14. In this way, the dose control of the drug 14 can be directly controlled by the plurality of grooves 111 of the drug-loading substrate|11, for example, the number and size of the grooves 111, the shape, etc. can be designed according to different needs. Manufacturing. The upper portion of the drug-loading substrate 11 is covered with a casing 12, and a rotation actuating mechanism 13 is disposed between the drug-loading substrate 11 and the casing 丨2 to drive the casing 12 to rotate above the drug-loading substrate π. The outer casing 12 can have a circular sheet-like structure with an ultra-thin thickness, the outer diameter is slightly larger than the drug-loading substrate 11, and the outer casing 12 has an opening 121 opening.

The pore size of 121 is about one third of the diameter of the groove of the drug-loading substrate 11, and the position of the opening 121 corresponds to the position of the hole 丨丨2 on the drug-loading substrate 11, and the outer casing 12 is placed on the drug-loading substrate 11 The front side is coupled to the axis of the rotary actuating mechanism 13 to rotate with the rotation of the actuating mechanism 13 for one cycle, for example, a period of 60 days, which can be rotated 360/60 degrees per day, that is, rotated by 6 degrees. If there are 30 holes 112 in the drug substrate 11, the interval between each hole 112 is 360/30 degrees, that is, 12 degrees, so that the opening 121 can pass through a groove ill every two days. When the opening 121 reaches the groove 111, the drug 14 in the groove ill is brought into contact with the blood of the human body, thereby releasing the drug 14 into the human body. 095145276 Form No. A0101 Page 8 of 14 0993195987-0 [0017] [0017]

Objective, the rotary actuating mechanism 13 of the present invention further comprises a shaft axis ΐ3ι, which is combined with the transmission _ automatic 机 machine core and transmission (four) hair rhyme to cooperate with the micro MEMS process, and the automatic clock machine mechanism and the spring parts use micro-mechanical The process is retracted in the rotary actuating mechanism 13, so that the automatic timing mechanism for the simple and externally small amount of the shaft sleeve 131 can be provided, and the automatic counting mechanism can be controlled by the external force. The time at which the drug u is released each time 'of course, the rotation actuating mechanism 13 does not need to be as long as the rotation period of the rotation cycle of the 131 (for example, the rotation of one cycle is (10) days as a basic design). The rotation actuating mechanism 13 is then disposed in the hole 113 in the back of the drug-loading substrate u (as shown in the second figure), and the rotating shaft center 131 passes through the center of the drug-loading substrate 11 and protrudes above the front surface of the casing 12. Thereby, the S-Xuan or 12 is rotated above the drug-loading substrate 11.

June 2, 099 Please refer to the third®, which is intended to be an embodiment of the reduction. In the embodiment, as shown in the figure, in order to achieve the timing and quantification of the same timepiece, there are counting functions such as counting and counting, etc., we only need to let the design change according to various timeliness requirements during design. In addition, in order to further protect the drug 14 of the plurality of grooves 1 that has not been released into the human body, the drug-loading substrate may further comprise a film m〇 covering the plurality of concaves Above the tank 111, to prevent the drug from reacting with the human body in advance. Of course, the sealing film 1110 can be dissolved in the blood of the human body, so that when the opening 121 of the outer casing 12 reaches above the groove in, the sealing film 1110 covering the groove 111 will pass through the opening 121, and the person Zhao Zhong The blood contacts to melt and rupture, thereby causing the drug in the groove 111 to come into contact with the blood of the human body, thereby releasing the drug into the human body. [0019] In addition, in the example that can be implemented by the technical concept of the present invention, 095145276 Form No. A0101 Page 9 of 14 0993195987-0 1329518 June 2, 2008

Because the size of a person may be very tall and fat, the size of the wafer, in addition to the small volume of the circular wafer used in the above embodiment, must have more different considerations, which can be based on the body type Make appropriate changes, but the premise must be that the patient or the implanted person is not physically fit or inconvenient, mainly based on the principle of light, thin, short and small. In addition, the choice of materials must also have a considerable degree of compatibility with the human body. Basic biomedical materials need to be non-toxi c ty, and will not cause hemolysis, immunity, inflammation and other reactions. In addition, the material needs to be sterilizable (s ter i 1 i zab i 1 -ity) and can be sterilized using techniques such as pressure cooker, E.O., plasma, ozone, and 7-ray. In addition, biomedical materials need to have so-called biocompatibility. These are all prerequisites for our choice of biomedical materials.

[0020] Further, after the basic elements such as the size material of the biochip are determined, the drugs and periodicity carried by the biochip are then considered, in other words, for the patient or the implanted person. The time of the drug received, the number of times the drug is needed, and the dose of the drug required are fully considered, and according to these points, the two structures of timing and metering in the biochip, that is, the number, size and shape of the grooves And the corresponding adjustment between the actuation of the rotating mechanism. When the overall design of the biochip is complete, the process is further implemented. The MEMS technology is used to model and assemble the parts of the biochip. Of course, after the completion of the biochip entity, a series of rigorous biochemical experiments are required. The preliminary biological experiments include experiments simulating human implants and implanting experimental wafers into the body of the animal, directly in the animal 095145276 Form No. A0101 Page 10 of 14 Page 0993195987-0 1329518 On June 2, 099, the page was replaced by the positive page. After the initial biochemical experiment is completed, the observation is extended to the direct clinical trial of the human body. During the experiment, all occurrences and any events that may occur in the moonlight must be considered, and the biodistribution of the drug release should be corrected for these conditions. [0021纟 合 以上 ' ' ' 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本The most difficult problem in drug release – timing and quantification of drug release; this will provide a more convenient and time-saving way of applying drugs that must be performed in the human body over time and repeatedly in the medical community, It is a great evangelism for patients who need to take long-term medications. It is also expected that this creation will bring benefits to the medical community and patients in the near future. [0022] Even though the present invention has been described in detail by the above embodiments It can be modified by people who are familiar with the art, but it is not intended to be attached to the scope of the patent application. Caregivers. BRIEF DESCRIPTION OF THE DRAWINGS [0023] First: A front view of a preferred embodiment of the present invention. [0024] Second drawing: a side cross-sectional view of a preferred embodiment of the present invention [0025] Third drawing: a schematic diagram of an embodiment of a rotary actuating mechanism of the present invention [Description of main components] [0026] 10 biofilm for drug release _] 11 drug carrier substrate 095145276 Form No. A0101 Page 11 / Total 14 Page 0993195987-0 1329518 099 June 02 Shuttle Zheng Page [0028] 111 Groove [0029] 111 0 Sealing film [0030] 1 1 2 Hole [0031] 12 Shell [0032] 1 2 1 Opening [0033] 13 Rotary Actuator [0034] 1 3 1 Shaft Axis [0035] 1 4 Drug

095145276 Form No. A0101 Page 12 of 14 0993195987-0

Claims (1)

June 2, 099 Shuttle replacement page 1329518 VII. Patent application scope: 1. A biochip implanted in a human body for releasing a drug to the human body, the biochip comprising: a drug-loading substrate Having a plurality of grooves, the grooves respectively carrying the drug, wherein the drug-loading substrate further comprises a film covering the plurality of grooves for preserving that the body has not been released into the body The drug; an outer casing disposed above the drug-loading substrate and covering the drug-loading substrate, the outer casing further comprising an opening; a rotary actuating mechanism disposed between the drug-loading substrate and the outer casing and driving the outer casing to rotate over the drug-loading substrate; thereby, when the opening rotates with the outer casing, sequentially passes the plurality When the grooves are above the ridge, the drug in the plurality of grooves is released to the human body through the opening. The biochip of claim 1, wherein the film is soluble in the blood of the human body. The biochip of claim 1, wherein the rotary actuating mechanism further comprises a spindle axis. The biochip of claim 3, wherein the spindle axis comprises an automatic clock machine core and a clockwork mechanism. The biochip of claim 3, wherein the spindle axis is machined in a micro-micro mechanical process. The biochip of claim 3, wherein the spindle axis passes through the drug-loading substrate and protrudes from the outer casing to drive the outer casing to rotate over the drug-loading substrate. 095145276 Form No. A0101 Page 13 of 14 0993195987-0